ADVB — ADVANCED BIOMED Income Statement
0.000.00%
Last trade - 00:00HealthcareMicro Cap
Annual income statement for ADVANCED BIOMED, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A |
| Standards: | USG | USG |
| Status: | Final | Final |
| Total Revenue | 0 | 0 |
| Selling / General / Administrative Expenses | ||
| Research And Development | ||
| Unusual Expense / Income | ||
| Total Operating Expenses | 1.84 | 3.99 |
| Operating Profit | -1.84 | -3.99 |
| Total Net Non Operating Interest Income / Expense | ||
| Other Net Non Operating Costs | ||
| Net Income Before Taxes | -1.84 | -4.03 |
| Provision for Income Taxes | ||
| Net Income After Taxes | -1.84 | -4.03 |
| Net Income Before Extraordinary Items | ||
| Net Income | -1.84 | -4.03 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | -1.84 | -4.03 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -0.019 | -0.024 |